Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finan...
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The presentation details are as follows: Title : Preclinical Activity of ARV-806, a PROTAC KRAS G12D Degrader Presentation Type : Poster presentation Poster Number : B107 Session : Poster Session B Date : October 24, 2025 Time : 12:30-4pm ET The full abstract can be accessed via the AACR-NCI-EORTC online program About ARV-806 ARV-806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. Therefore, ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic,
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Arvinas (NASDAQ:ARVN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.MarketBeat
- Arvinas (NASDAQ:ARVN) was given a new $18.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.MarketBeat
- How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating [Yahoo! Finance]Yahoo! Finance
- Arvinas (NASDAQ:ARVN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ARVN
Earnings
- 11/5/25 - Beat
ARVN
Sec Filings
- 12/8/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- ARVN's page on the SEC website